Ben Dickie

Abstract Resection surgery is the first-line therapy for glioblastoma (GBM) that is performed in >70% of patients, typically within days of suspected diagnosis. Current protocols for follow-on chemoradiotherapy have shown only modest efficacy in eliminating residual disease, leading to inevitable tumour recurrence. There remains a need for new approaches to swiftly and effectively treat post-operative residual disease to prevent the rapid early progression of recurrent GBM.

1 INTRODUCTION The blood–brain barrier (BBB) plays a vital role in regulating and maintaining healthy brain function. Passive diffusion of solutes and potential neurotoxins from the blood into the brain is tightly restricted, with the transport of necessary metabolites controlled by specialized proteins.